Qualigen Therapeutics Files 8-K
Ticker: AIXC · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1460702
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Qualigen Therapeutics filed an 8-K today, check for updates.
AI Summary
On September 20, 2024, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Qualigen Therapeutics is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific details of material events or financial performance.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- September 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37428 (filing_id) — Commission File Number
- 26-3474527 (tax_id) — I.R.S. Employer Identification No.
- 5857 Owens Avenue , Suite 300 , Carlsbad , California 92008 (address) — Address of principal executive offices
- (760) 452-8111 (phone_number) — Registrant's telephone number
FAQ
What specific information is being disclosed in this 8-K filing?
The filing indicates it pertains to Regulation FD Disclosure and Financial Statements and Exhibits, but the specific details are not provided in the excerpt.
When was the earliest event reported in this filing?
The earliest event reported was on September 20, 2024.
What is the principal executive office address for Qualigen Therapeutics, Inc.?
The principal executive office is located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the Commission File Number for Qualigen Therapeutics, Inc.?
The Commission File Number is 001-37428.
What is the IRS Employer Identification Number for Qualigen Therapeutics, Inc.?
The IRS Employer Identification Number is 26-3474527.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-09-20 16:10:16
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-037600.txt ( ) — 226KB
- qlgn-20240920.xsd (EX-101.SCH) — 3KB
- qlgn-20240920_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240920_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 20, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer